Turkish Journal of Hematology最新文献

{"title":"Importance of Rare Gene Alterations in the Prognosis of B-Cell Acute Lymphoblastic Leukemia","authors":"Li Xiang, Yongliang Wang, Wei Pan","doi":"10.4274/tjh.galenos.2024.2023.0400","DOIUrl":"10.4274/tjh.galenos.2024.2023.0400","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"49-50"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rifampicin-Induced Toxic Hepatitis in a Patient with Hemophilia After Chemical Synovectomy","authors":"Mehmet Can Uğur, Semih Aydoğdu, Elçil Kaya Biçer, Can Balkan, Kaan Kavaklı","doi":"10.4274/tjh.galenos.2024.2023.0420","DOIUrl":"10.4274/tjh.galenos.2024.2023.0420","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"64-65"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of <i>CALR</i> and <i>JAK2</i>V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.","authors":"Zehra Narlı Özdemir, Yıldız İpek, Püsem Patır, Gözde Ermiş, Rafiye Çiftçiler, Deniz Özmen, Mehmet Baysal, Vildan Gürsoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakuş, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eşkazan","doi":"10.4274/tjh.galenos.2024.2023.0430","DOIUrl":"10.4274/tjh.galenos.2024.2023.0430","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we investigated the effects of calreticulin (<i>CALR</i>) and <i>JAK2</i>V617F mutational status on clinical course and disease outcomes in Turkish patients with essential thrombocythemia (ET).</p><p><strong>Materials and methods: </strong>Seventeen centers from Türkiye participated in the study and <i>CALR</i>- and <i>JAK2</i>V617F-mutated ET patients were evaluated retrospectively.</p><p><strong>Results: </strong>A total of 302 patients were included, of whom 203 (67.2%) and 99 (32.8%) were <i>JAK2</i>V617F- and <i>CALR</i>-positive, respectively. <i>CALR</i>-mutated patients were significantly younger (51 years vs. 57.5 years, p=0.03), with higher median platelet counts (987x10⁹/L vs. 709x10⁹/L, p<0.001) and lower median hemoglobin levels (13.1 g/dL vs. 14.1 g/dL, p<0.001) compared to <i>JAK2</i>V617F-mutated patients. Thromboembolic events (TEEs) occurred in 54 patients (17.9%), 77.8% of which were arterial. Compared to <i>CALR</i> mutation, <i>JAK2</i>V617F was associated with a higher risk of thrombosis (8.1% vs. 22.7%, p=0.002). Rates of transformation to myelofibrosis (MF) and leukemia were 4% and 0.7%, respectively, and these rates were comparable between <i>JAK2</i>V617F- and <i>CALR</i>-mutated cases. The estimated overall survival (OS) and MF-free survival of the entire cohort were 265.1 months and 235.7 months, respectively. OS and MF-free survival durations were similar between <i>JAK2</i>V617F- and <i>CALR</i>-mutated patients. Thrombosis-free survival (TFS) was superior in <i>CALR</i>-mutated patients compared to <i>JAK2</i>V617F-positive patients (5-year TFS: 90% vs. 71%, respectively; p=0.001). Age at diagnosis was an independent factor affecting the incidence of TEEs.</p><p><strong>Conclusion: </strong>In our ET cohort, <i>CALR</i> mutations resulted in higher platelet counts and lower hemoglobin levels than <i>JAK2</i>V617F and were associated with younger age at diagnosis. <i>JAK2</i>V617F was strongly associated with thrombosis and worse TFS. Hydroxyurea was the most preferred cytoreductive agent for patients with high thrombosis risk.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":"41 1","pages":"26-36"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiphospholipid Syndrome: To Classify or Not to Classify?","authors":"Doruk Erkan","doi":"10.4274/tjh.galenos.2024.2024.0003","DOIUrl":"10.4274/tjh.galenos.2024.2024.0003","url":null,"abstract":"<p><p>Antiphospholipid syndrome (APS) is a systemic autoimmune disorder resulting in thrombosis, microvascular disease, morbidity in pregnancy, and/or non-thrombotic manifestations. The recently introduced 2023 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) APS classification criteria, with significantly higher specificity compared to the revised Sapporo criteria, now reflect the current thinking about APS and provide a new foundation for future APS research. The purpose of this short commentary is to discuss the appropriate circumstances under which the 2023 ACR/EULAR classification criteria could be used and to demonstrate how the new criteria can be applied to simple case scenarios.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"37-40"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction","authors":"Simge Erdem, Meliha Nalçacı","doi":"10.4274/tjh.galenos.2023.2023.0426","DOIUrl":"10.4274/tjh.galenos.2023.2023.0426","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"55-56"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138831697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia.","authors":"Ayşe Kaya, İbrahim Aras, Pervin Özkan Kurtgöz, Umut Çakıroğlu","doi":"10.4274/tjh.galenos.2023.2023.0368","DOIUrl":"10.4274/tjh.galenos.2023.2023.0368","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":"41 1","pages":"57-58"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis","authors":"Martyna Włodarczyk, Agata Wieczorkiewicz-Kabut, Krzysztof Białas, Anna Koclęga, Izabela Noster, Patrycja Zielińska, Grzegorz Helbig","doi":"10.4274/tjh.galenos.2024.2024.0026","DOIUrl":"10.4274/tjh.galenos.2024.2024.0026","url":null,"abstract":"<p><strong>Objective: </strong>Cytomegalovirus (CMV) reactivation is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). Introduction of letermovir (LMV) seems to improve post-transplant outcomes, but delayed-onset CMV reactivation still remains a challenge. In this study, we report on our first experience with LMV prophylaxis in 93 CMV-seropositive adult patients receiving HSCT in our center.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed the data of 93 adult CMV-seropositive recipients receiving LMV as CMV prophylaxis after HSCT for hematological malignancies between 2019 and 2023. The starting LMV dose was 480 mg daily, reduced to 240 mg daily for those receiving cyclosporin A co-administration. CMV DNA in the blood was measured by real-time polymerase chain reaction weekly for the first 2 months after transplantation, then every other week until the end of immunosuppressive treatment. LMV was continued to day +100 or to CMV reactivation.</p><p><strong>Results: </strong>The median recipient age at the time of transplant was 51 (range: 20-71) years. All patients received grafts from peripheral blood, mostly for acute myeloid leukemia (60%). The median time from transplantation to LMV initiation was 3 (range: 0-24) days. While 55% of patients were transplanted from matched related donors, 32% had unrelated donors and 13% underwent haploidentical HSCT. Four patients (4%) had CMV “blips” while on LMV, but the drug was continued and repeated assays were negative. Only 2 patients (2%) experienced CMV reactivation while on LMV, on days 48 and 34 after HSCT, respectively. Seven patients (7%) developed late-onset CMV reactivation after a median of 124 days after HSCT (range: 118-152 days) and they were successfully treated with ganciclovir. CMV disease was not observed. Grade III-IV acute graft-versus-host disease occurred in 6 patients (6%) during LMV treatment. LMV treatment was free of side effects.</p><p><strong>Conclusion: </strong>LMV prophylaxis was effective in preventing CMV reactivation with a favorable safety profile. CMV reactivation occurred mostly after LMV discontinuation; thus, extending the duration of prophylaxis beyond 100 days could be beneficial.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"9-15"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Clasmatosis Morphology","authors":"Antonio La Gioia, Miriam Marsano, Fabiana Fiorini","doi":"10.4274/tjh.galenos.2023.2023.0275","DOIUrl":"10.4274/tjh.galenos.2023.2023.0275","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"45-46"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41135153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncolytic <i>Myxoma virus</i> Increases Autophagy in Multiple Myeloma","authors":"Alpay Yeşilaltay, Dilek Muz, Berna Erdal","doi":"10.4274/tjh.galenos.2024.2023.0403","DOIUrl":"10.4274/tjh.galenos.2024.2023.0403","url":null,"abstract":"<p><strong>Objective: </strong>Multiple myeloma, which affects plasma cells, is the second most common hematological malignancy. Despite the development of new drugs and treatment protocols, patient survival has not reached the desired level. In this study, we investigated the effects of <i>Myxoma virus</i> (MYXV), an oncolytic virus, on autophagy in myeloma cells.</p><p><strong>Materials and methods: </strong>We analyzed protein expressions of ATG-5, p62, Beclin-1, LC3B, and the apoptosis marker Bcl-2 as autophagy markers in human U-266 and mouse MOPC-315 myeloma cell lines subjected to different doses of MYXV. In addition, autophagic images of myeloma cells were investigated using transmission electron microscopy (TEM).</p><p><strong>Results: </strong>In the first 24 h, which is the early stage of autophagy, ATG-5 and Beclin-1 expression levels were increased in the U-266 and MOPC-315 cell lines in the groups that had received MYXV at a multiplicity of infection of 15. At 48 h, a significant increase was detected in the expression of LC3B, which is a late indicator. Autophagosomes were observed in myeloma cells by TEM.</p><p><strong>Conclusion: </strong>MYXV shows an antimyeloma effect by increasing autophagy in myeloma cells.</p>","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"16-25"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139522069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report","authors":"Yu-Han Gao, Ming-Hui Duan, Jian Li, Lu Zhang","doi":"10.4274/tjh.galenos.2024.2023.0477","DOIUrl":"10.4274/tjh.galenos.2024.2023.0477","url":null,"abstract":"","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"61-63"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}